SCHEMBL2471683

SCHEMBL2471683

CC[C@](N)(CCCCN)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ARG2 P78540 12/20 0.65
ARG1 P05089 11/20 0.65
MEN1 O00255 1/20 0.59
ALDH1A1 P00352 1/20 0.59
CYP1A2 P05177 1/20 0.59
THRB P10828 1/20 0.59
KMT2A Q03164 1/20 0.59
ODC1 P11926 2/20 0.57
KDM4E B2RXH2 1/20 0.40
LMNA P02545 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
BLM P54132 1/20 0.40
PMP22 Q01453 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CYP2D6 P10635 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7198295 1.00 ARG2 (0.65) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL5322729 0.98 ARG2 (0.62) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL5320097 0.98 ARG2 (0.62) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL4884643 0.94 ODC1 (0.64) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL4884638 0.94 ODC1 (0.64) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL4884641 0.94 ODC1 (0.64) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL8842963 0.85 ARG2 (0.67) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL5324175 0.85 MEN1 (0.65) ARG2ARG1MEN1ALDH1A1CYP1A2
SCHEMBL29359936 0.85 ODC1 (0.63) ARG2ARG1ODC1KDM4ELMNA
SCHEMBL264841 0.84 ODC1 (0.53) ARG2ARG1MEN1ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0723552-B1 OLIGOPEPTIDES DERIVED FROM C-REACTIVE PROTEIN FRAGMENTS ITALFARMACO SPA (IT) 2002-10-23 EP claimed
US-6342481-B1 RESIDUES OF THREONINE, LEUCINE, ISOLEUCINE, VALINE, SARCOSINE, ALANINE, GLYCINE AND ACYLGLYCINE ITALFARMACO S.P.A. (IT) 2002-01-29 US claimed
EP-3990478-A1 TNF MUTEINS AND USES THEREOF Oxford University Innovation Limited (GB) 2022-05-04 EP disclosed
EP-1133309-B1 Composition and methods for neural tissue repair INST MEDICAL W & E HALL (AU) 2011-10-05 EP disclosed
US-6602910-B2 Treating cancer in a patient comprising administering an effective amount of substantially purified D enantiomer of difluoromethylornithine ILEX ONCOLOGY, INC. 2003-08-05 US disclosed
US-20020045663-A1 D-enantiomer of DFMO and methods of use therefor ILEX ONCOLOGY, INC. (US) 2002-04-18 US disclosed
US-4339589-A Preparation of 4-substituted oxazolidin-5-ones BASF AKTIENGESELLSCHAFT (DE) 1982-07-13 US disclosed
US-4264771-A Alkylation of substituted oxazolinone-(5) compounds BASF AKTIENGESELLSCHAFT (DE) 1981-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020045663-A1 D-enantiomer of DFMO and methods of use therefor DHODH, DDT, HADHB ARG2 819/4885ARG1 605/4885MEN1 164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.